Annals of Oncology 15:1161-1171, 2004
© 2004 European Society for Medical Oncology
Review |
Primary chemotherapy for breast cancer: the evidence and the future
The first generation of randomised trials assessing the role of primary chemotherapy in breast cancer has failed to demonstrate the expected survival benefit. However, it has established the role of this treatment in downstaging tumours of patients with locally advanced disease and, consequently, in improving breast conservation rates. Also, a number of surrogates of outcome have been identified, which will hopefully lead to earlier results in breast cancer clinical trials. Encouraging results have also been reported in trials investigating a number of novel approaches.
1 Beatson Oncology Centre, Department of Medical Oncology, Glasgow, UK; 2 Institut Jules Bordet, Unité de Chimiothérapie, Brussels, Belgium
* Correspondence to: Dr M. S. Mano, Beatson Oncology Centre, Department of Medical Oncology, Dumbarton Road, Glasgow G11 6NT, UK. Tel: +44-141-2116299; Fax: +44-141-2111866; E-mail: max_mano{at}hotmail.com
Key words: breast cancer, breast conserving surgery, neoadjuvant chemotherapy, primary chemotherapy
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. A. Cahill, D. Walsh, R. J. Landers, and R. G. Watson Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core Biopsy Ann. Surg. Oncol., January 1, 2006; 13(1): 45 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kerr Teenage kicks Ann. Onc., January 1, 2005; 16(1): 1 - 2. [Full Text] [PDF] |
||||

